Shulamit Ron-Bigger has served as Aktis Oncology's Chief Operating Officer since September 2022. She previously served as Vice President of Portfolio Strategy for the Research and Early Development organization at Bristol Myers Squibb, where she held various strategic and commercial roles from 2017, and earlier worked as a strategic consultant to large pharmaceutical companies. She holds a PhD in Cancer Epigenetics from The Hebrew University of Jerusalem and a BA in Molecular Biochemistry from the Technion - Israel Institute of Technology.